Retinol palmitate - Advent Therapeutics
Alternative Names: Vitamin A palmitate - Advent Therapeutics; Water miscible vitamin A palmitate - Advent TherapeuticsLatest Information Update: 28 Aug 2023
At a glance
- Originator Advent Therapeutics
- Class Eye disorder therapies; Retinoids; Vitamins
- Mechanism of Action Antioxidants; Vitamin A replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute lung injury; Bronchopulmonary dysplasia; Retinopathy of prematurity
Most Recent Events
- 28 Aug 2023 Chemical structure information added
- 25 Jul 2023 Retinol palmitate receives Rare Paediatric Disease Designation (RPDD) designation from the US FDA for Bronchopulmonary dysplasia (In infants, Prevention)
- 20 Jul 2023 Advent Therapeutics plans PDUFA Meeting with the US FDA to establish approval pathway, in late 2023